Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal JSFK (Jurnal Sains Farmasi & Klinis) Medical and Health Science Journal
Massey, Firdaus Kabiru
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health Social Sciences

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
REVIEW ARTICLE: DEVELOPEMENT AND USING DENGUE VACCINE FOR DENGUE INFECTION VIRUS Massey, Firdaus Kabiru; Yulia, Rika
Jurnal Ilmu Kesehatan dan Kesehatan Vol 3 No 2 (2019): AUGUST
Publisher : UNUSA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33086/mhsj.v3i2.1194

Abstract

Abstract : Tropical and subtropical countries are regions with high incidence of dengue infection. Dengue virus infection is estimated to cause 300 million new infections in one year and approximately 1 million severe cases with 2 + 5% deaths. The case of dengue in Indonesia has continued to increase since 1968 until 1980 where all provinces in Indonesia have been affected by the dengue virus. Dengue virus is a virus carried by the Aedes aegypti mosquito in its salivary gland. The virus which is a family group of Flaviviruses has four homologous serotypes, namely DENV-1, DENV-2, DENV-3, and DENV-4, which can cause dengue infection in individuals. Currently there is a shift in the target population from children to adults. This is a problem that needs to be resolved by the government and the community itself. Solution to overcome this, the government needs early prevention efforts to reduce the severity of dengue infection by developing and researching dengue vaccines. Currently a vaccine has been found that can be used as prophylaxis for dengue virus, namely Dengvaxia. This vaccine has been recommended by the World Health Organization (WHO) as prophylaxis for dengue infection, but Dengvaxia is only used in areas that are very endemic to dengue fever. The Indonesian Food and Drug Supervisory Agency (BPOM RI) has also approved the use of Dengvaxia as an indication of prevention of dengue infection since August 31, 2016. This vaccine has been approved globally only given to individuals aged between 9-16 years.  Keyword : dengue virus, dengvaxia vaccine, Aedes aegypti, endemic
REVIEW ARTICLE: DEVELOPEMENT AND USING DENGUE VACCINE FOR DENGUE INFECTION VIRUS Massey, Firdaus Kabiru; Yulia, Rika
Jurnal Ilmu Kesehatan dan Kesehatan Vol 3 No 2 (2019): AUGUST
Publisher : UNUSA Press

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33086/mhsj.v3i2.1194

Abstract

Abstract : Tropical and subtropical countries are regions with high incidence of dengue infection. Dengue virus infection is estimated to cause 300 million new infections in one year and approximately 1 million severe cases with 2 + 5% deaths. The case of dengue in Indonesia has continued to increase since 1968 until 1980 where all provinces in Indonesia have been affected by the dengue virus. Dengue virus is a virus carried by the Aedes aegypti mosquito in its salivary gland. The virus which is a family group of Flaviviruses has four homologous serotypes, namely DENV-1, DENV-2, DENV-3, and DENV-4, which can cause dengue infection in individuals. Currently there is a shift in the target population from children to adults. This is a problem that needs to be resolved by the government and the community itself. Solution to overcome this, the government needs early prevention efforts to reduce the severity of dengue infection by developing and researching dengue vaccines. Currently a vaccine has been found that can be used as prophylaxis for dengue virus, namely Dengvaxia. This vaccine has been recommended by the World Health Organization (WHO) as prophylaxis for dengue infection, but Dengvaxia is only used in areas that are very endemic to dengue fever. The Indonesian Food and Drug Supervisory Agency (BPOM RI) has also approved the use of Dengvaxia as an indication of prevention of dengue infection since August 31, 2016. This vaccine has been approved globally only given to individuals aged between 9-16 years. Keyword : dengue virus, dengvaxia vaccine, Aedes aegypti, endemic
Profil Kualitas dan Kuantitas Penggunaan Antibiotik Profilaksis pada Pre, On, dan Pos Bedah di Rumah Sakit Provinsi (RSP) NTB Massey, Firdaus Kabiru; Yulia, Rika; Muliani, Nurlina; Herawati, Fauna
JSFK (Jurnal Sains Farmasi & Klinis) Vol 8 No 1 (2021): J Sains Farm Klin 8(1), April 2021
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.8.1.43-52.2021

Abstract

Penelitian ini bertujuan untuk mengetahui profil kuantitas penggunaan antibiotik berdasarkan metode DDD/100 patient-days dan kualitas penggunaan antibiotik berdasarkan persentase kesesuaian (indikasi, waktu pemberian, durasi, dosis, dan rute pemberian) terhadap ASHP, PPAB, dan Formularium Rumah Sakit, serta profil Infeksi Daerah Operasi (IDO) pada pasien bedah di RSP NTB periode Januari-Juni 2019. Metode penelitian menggunakan desain penelitian deskriptif dengan pengambilan data secara retrospektif terhadap data rekam medik sampel penelitian. Subyek penelitian adalah pasien bedah periode Januari-Juni 2019 yang memenuhi kriteria inklusi, yaitu sebanyak 323 sampel penelitian. Hasil yang diperoleh dari penelitian ini yaitu kuantitas penggunaan antibiotik periode Januari-Juni 2019 di dominasi oleh antibiotik ceftriaxone (J01DD04) dengan nilai total DDD/100 patient-days pada pre operasi yaitu 77,655, on operasi 87,31, dan post operasi 93,65. Kesesuaian pemilihan antibiotik profilaksis berdasarkan guideline ASHP sebesar 1,9%, PPAB 15,5%, dan Formularium RSP NTB 100%, sedangkan kesesuaian durasi, waktu pemberian, dosis, dan rute pemberian berdasarkan ASHP berturut-turut yaitu 19,2%, 42,7%, 1,5%, dan 100%. Sampel penelitian yang mengalami IDO yaitu 2 dari 323 sampel (0,62%) dengan hasil pertumbuhan bakteri yaitu Proteus sp., Staphylococcus aureus, S. epidermidis, dan E.coli. Uji sensitivitas keseluruhan bakteri penyebab IDO ditemukan masih sensitif terhadap antibiotik seperti chloramphenicol, amoxicillin-clavulanic acid, vancomycin, cefoxitin, dan oxacillin
Co-Authors Herawati, Fauna Muliani, Nurlina Rika Yulia